According to American Heart Association, Acute Coronary Syndrome(ACS) is an umbrella term that refers to a spectrum of conditions compatible with acute myocardial ischemia and/or infarction that are usually due to an abrupt reduction in coronary blood flow. The traditional types of ACS comprise of myocardial infarction with ST-segment elevation (STEMI), which generally reflects an acute total coronary occlusion, myocardial infarction without ST-segment elevation (NSTEMI), and unstable angina (UA), with or without myocardial injury, respectively.
Key components in the management of ACS include coronary revascularization when indicated, prompt initiation of dual antiplatelet therapy and anticoagulation; and consideration of adjuvant agents including β blockers, inhibitors of the renin-angiotensin system, and HmG-coenzyme A reductase inhibitors. It is essential for clinicians to take an individualized approach to treatment and consider long-term safety and efficacy when managing patients with a history of ACS after hospital discharge.
Substantial progress in the prevention, diagnosis and management of patients with ACS has been accomplished in recent years. Despite optimal pharmacological and invasive therapies, the burden of recurrent ischemic events and mortality remains high, and future research is ongoing to prevent and improve patients’ outcomes with ACS.
Get FREE sample copy at: https://www.delveinsight.com/sample-request/acute-coronary-syndrome-market
The Acute Coronary Syndrome market report also covers emerging drugs, current treatment practices, Acute Coronary Syndrome market share of the individual therapies, current and forecasted Acute Coronary Syndrome Market Size from 2017 to 2030 segmented by seven major markets.
The report provides a detailed current Acute Coronary Syndrome treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Acute Coronary Syndrome Market Key Facts
-
According to the American Heart Association, an estimated 5–8 million patients present to the ED annually for chest pain, and 20–25% diagnosed with Acute Coronary Syndrome.
-
As per the results of a study conducted by Ballerino et al. (2020), patients diagnosed with ACS resulted in being statistically significantly older than those without ACS, with a higher prevalence of males (66.1% in ACS vs. 57.5% in NO ACS).
-
According to a study conducted in Japan by Daida et al. (2013), ST-segment elevation myocardial infarction (STEMI) was the most frequent type of ACS (59.4%). The vast majority (93.5%) of patients underwent percutaneous coronary intervention (PCI), with a success rate of 93.9%.
Key Benefits of Acute Coronary Syndrome Market Report
-
Acute Coronary Syndrome market report provides an in-depth analysis of Acute Coronary Syndrome Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major markets, i.e. EU5 (Germany, Italy, Spain, France, and the UK), Japan, and the United States.
-
The Acute Coronary Syndrome market report will help in developing business strategies by understanding the Acute Coronary Syndrome Market trends & developments, key players, and future market competition that will shape and drive the Acute Coronary Syndrome market in the upcoming years.
-
The Acute Coronary Syndrome market report covers Acute Coronary Syndrome current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
-
The report provides a detailed assessment of the Acute Coronary Syndrome market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population, comparative analysis of pipeline products with detailed clinical profiles, and other factors.
Acute Coronary Syndrome Market
The Acute Coronary Syndrome market size is expected to increase during the forecast owing to the increasing incident population of ACS patients in the 7MM
The Acute Coronary Syndrome market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Acute Coronary Syndrome market trends by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.
The report gives a thorough detail of the Acute Coronary Syndrome market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Acute Coronary Syndrome Epidemiology
The Acute Coronary Syndrome epidemiology section covers insights about the historical and current Acute Coronary Syndrome patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Acute Coronary Syndrome Drugs Uptake and Key Market Players
The Acute Coronary Syndrome Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Acute Coronary Syndrome market or expected to get launched in the market during the study period. The analysis covers Acute Coronary Syndrome market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The available therapeutics treatment options in ACS Landscape aim to improve blood flow, treat complications and prevent future problems. Research is underway to identify treatment approaches that may address some of the challenges to existing treatment.
Some of the key players, such as Regeneron, Sanofi, DalCor Pharmaceutical, and CSL Behring are involved in developing therapies for the treatment of Acute Coronary Syndrome.
Acute Coronary Syndrome therapies covered in the report include:
Alirocumab
Dalcetrapib
CSL112
And many others.
Table of Content
1. Key Insights
2. Executive Summary
3. Acute Coronary Syndrome Competitive Intelligence Analysis
4. Acute Coronary Syndrome Market Overview at a Glance
5. Acute Coronary Syndrome Disease Background and Overview
6. Acute Coronary Syndrome Patient Journey
7. Acute Coronary Syndrome Epidemiology and Patient Population
8. Acute Coronary Syndrome Treatment Algorithm, Current Treatment, and Medical Practices
9. Acute Coronary Syndrome Unmet Needs
10. Key Endpoints of Acute Coronary Syndrome Treatment
11. Acute Coronary Syndrome Marketed Products
12. Acute Coronary Syndrome Emerging Therapies
13. Acute Coronary Syndrome Seven Major Market Analysis
14. Attribute Analysis
15. Acute Coronary Syndrome Market Outlook (7 major markets)
16. Acute Coronary Syndrome Access and Reimbursement Overview
17. KOL Views on the Acute Coronary Syndrome Market.
18. Acute Coronary Syndrome Market Drivers
19. Acute Coronary Syndrome Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.
Get FREE sample copy at: https://www.delveinsight.com/sample-request/acute-coronary-syndrome-market
Latest Reports By DelveInsight
Acute Coronary Syndrome Pipeline Insights
Acute Coronary Syndrome Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Acute Coronary Syndrome market.
Bevacizumab Biosimilars Insight
DelveInsight’s, “Bevacizumab Biosimilar Insight, 2020,” report provides comprehensive insights about 40+ companies and 40+ marketed and pipeline drugs in the Bevacizumab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and non-clinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/